Short signals on regulatory, pricing and procurement shifts, and what they change.
A 100 percent tariff on imported patented medicines is operative for a first group of companies, and applies to everyone else from 29 September.
WHO and the African Medicines Agency signed a framework to drive regulatory reliance across the continent.
An abbreviated assessment route opens for products already approved by one of six named authorities.
NICE's cost-effectiveness range moved for the first time in two decades, and the Secretary of State can now direct it.
A new GB route recognises US, Canadian and Australian approvals. Not European ones.